Zelira in the news
For media related enquiries please contact Damien Carbon at Profile Media
Ph: +61 (0) 412 332 122 E: email@example.com
PAEDIATRIC BRAIN CANCER RESEARCH UPDATE
Zelda Therapeutics Ltd (ASX: ZLD, US OTC: ZLDAF, Zelda or the Company) is pleased to provide an update on its previously announced paediatric brain cancer research project with the prestigious Telethon Kids Institute (“TKI” or “the Institute) in Perth, Western Australia.